BIRMINGHAM, England--(BUSINESS WIRE)--Recent technical research data reported that the GE FASTlab™ synthesizer combined with Solid Phase Extraction (SPE) and the application of chemometric tools showed an increase in reliability of the manufacturing1 and synthesis2 of [18F]Flutemetamol. [18F]Flutemetamol is a GE Healthcare Positron Emission Tomography (PET) investigational imaging agent currently in phase III development being studied for the detection of beta amyloid using PET brain scans.
